In Brief: Kremer LASIK PMA
This article was originally published in The Gray Sheet
Kremer LASIK PMA: Ophthalmologist and inventor Fredric Kremer's premarket approval application for single-site use of an excimer laser to perform Laser-K LASIK (laser in situ keratomileusis) procedures is scheduled for review by FDA's Ophthalmic Devices Panel on Feb. 13. Approval of the PMA, which encompasses treatment of myopia and myopic astigmatism at Kremer Laser Eye Center, in King of Prussia, Pennsylvania, would seal an agreement with LaserSight giving the company rights to the technology ("The Gray Sheet" Aug. 18, 1997, I&W-16). The Kremer PMA is not the first single-site LASIK PMA to go before the panel. In July 1997, the Ophthalmic panel unanimously recommended approval of a PMA from The Vision Correction Group, Atlanta ("The Gray Sheet" July 21, 1997, p. 10)...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.